

Report of the Fifth Meeting of the Pandemic Influenza Preparedness (PIP) Framework 2016 Review Group

ORGANIZATION AND PROCESS OF THE MEETING

1. The fifth meeting of the PIP Framework Review Group was held at WHO Headquarters from 27 June to 1 July. The meeting included in its agenda:
 - Interviews with key informants;
 - Interviews with WHO Regional Offices and heads of PIP Partnership Contribution's Areas of Work on pandemic influenza preparedness;
 - Discussion of draft Findings and Recommendations for the Final Report;
 - Webcast of key messages from the meeting.
2. Six of the eight members of the Review Group, attended the meeting (names and affiliations of the members are listed in Annex 1). Dr Viroj Tangcharoensathien and Prof Dr Makarim Wibisono were absent and sent apologies.

OPENING OF THE MEETING

3. Dr Christine Mwelwa Kaseba-Sata chaired the meeting. Dr Kaseba-Sata welcomed members to the meeting and outlined the agenda.

MEETING WITH WHO DIRECTOR-GENERAL

4. The Review Group met with WHO Director-General, Dr Margaret Chan, and Dr Anarfi Asamoah-Baah, Deputy Director-General, and provided an update on their analyses and work for the PIP Framework Review.

KEY INFORMANT INTERVIEWS

5. The Review Group members conducted interviews on: (1) the Nagoya Protocol, and implications of its implementation for the PIP Framework and public health; (2) the development and role of the Tool for Influenza Pandemic Risk Assessment (TIPRA).
6. The Review Group also interviewed a representative of a donor organization that funds influenza activities.

INTERVIEWS WITH KEY WHO INFORMANTS

7. The Review Group conducted interviews with representatives of WHO Regional Offices and analysed written submissions from all WHO Regional Offices, covering: (1) the main achievements in each region since the PIP Framework was adopted; (2) the impact of the PIP Framework in each region on pandemic influenza preparedness, including inter-pandemic surveillance and capacity to respond; (3) development and benefits of links with other programmes (e.g. IHR, Global Action Plan for Influenza Vaccines (GAP)); (4) level of knowledge about the PIP Partnership Contribution priority country recipient selection process; (5) the duration of PIP Framework funding; and (6) challenges and their possible resolution in PIP Framework implementation.
8. The Review Group received presentations from the heads of three of the five PIP Partnership Contribution's Areas of Work (AOW) on pandemic influenza preparedness: regulatory capacity building; risk communications; and planning for deployment. Discussions included progress to date on the implementation of work plans and their impact on global preparedness in the priority countries. [An interview with the lead of the other two Areas of Work (laboratory and surveillance capacity building; burden of disease) took place at the May 2016 Review Group meeting.]

ANALYSIS OF INTERVIEWS

9. The Review Group conducted detailed analysis of interviews conducted and submissions received to date.

DISCUSSION OF THE FINAL REPORT

10. The Group reviewed in detail the SWOT analysis on virus and benefit sharing, governance and linkages with other instruments/programmes (IHR, Nagoya and GAP); the results of interviews; Advisory Group reports; PC collection and implementation reports; and developed draft Findings and Recommendations for its Final Report.

NEXT STEPS

11. The Review Group considered next steps, including review of the submissions from Member States, which should be received no later than 15 July 2016 and the timetable for completion of the Final Report.
12. The Review Group approved the meeting report, and the Chair thanked the members and closed the meeting.

WEBCAST OF KEY MESSAGES FROM THE MEETING

13. The Chair held a webcast information session for Member States, summarizing the key outcomes of the meeting and inviting further participation by Member States and stakeholders in the process, notably by written submissions which should be received no later than 15 July 2016. The Chair also formally invited Member States and stakeholders to attend the open session on 29 August 2016 during the Review Group's final meeting at WHO Headquarters, Geneva.

ANNEX 1

MEMBERS OF THE REVIEW COMMITTEE

Review Group Members	Affiliation
Professor William Kwabena Ampofo	Head of Virology Department, Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana
Dr Christine Mwelwa Kaseba-Sata (Chair)	Former WHO Goodwill Ambassador against Gender-based Violence, Zambia
Dr Frances McGrath	Chief Advisor, Clinical Leadership, Protection and Regulation, Ministry of Health, New Zealand
Dr Talat Mokhtari-Azad,	Director, Iranian National Influenza Center
Ms Johanne Newstead	Head of Food Policy, Public Health Directorate, Department of Health, United Kingdom
Dr Theresa Tam	Assistant Deputy Minister, Infectious Disease Prevention and Control Branch, Public Health Agency of Canada
Dr Viroj Tangcharoensathien	Senior Adviser, International Health Policy Program, Ministry of Public Health, Thailand
Prof Dr Makarim Wibisono	Chairman, Governing Board of Indonesia Council of World Affairs